Kyoto University

The global cancer biomarkers market size was USD 31.90 billion in 2023 and is projected to reach USD 107.33 billion by 2033, growing at a CAGR of 12.9%. Key drivers include rising technical developments, individualized treatment approaches, and increasing prevalence of cancer globally. The breast cancer segment led the market in 2023, while the genetic biomarkers segment dominated in terms of revenue. North America held the largest market share in 2023, with the U.S. leading due to high prevalence of renal cancer and strong pipeline. Technological innovations and advancements in personalized medicine are expected to further fuel market growth.

Alloy Therapeutics introduces a new licensing model for its ATX-Gx antibody technology, eliminating annual fees and milestones, enhancing drug discovery. Collaborates with Sanofi on AntiClastic Antisense Platform for CNS targets and with Takeda on iPSC-derived CAR-T/NK platforms, aiming to revolutionize therapeutic development.